Benign prostatic hyperplasia is a prevalent urological condition affecting middle-aged and elderly men, characterized by progressive enlargement of the prostate gland and the development of lower urinary tract symptoms. These symptoms significantly impair patients’ quality of life and often necessitate medical intervention. Conservative treatment methods, including pharmacological therapy, serve as a first-line approach, particularly in patients with mild to moderate disease. This study evaluates the clinical outcomes of conservative management, focusing on symptom reduction, improvement of urinary function, and enhancement of quality of life. Results indicate that non-surgical therapy effectively alleviates lower urinary tract symptoms, stabilizes disease progression, and minimizes the need for surgical intervention. Early initiation and consistent adherence to conservative treatment are essential for achieving optimal outcomes and maintaining patient safety. Overall, conservative management provides a safe, effective, and patient-centered approach in the comprehensive care of benign prostatic hyperplasia.

Benign prostatic hyperplasia; lower urinary tract symptoms; conservative treatment; pharmacological therapy; quality of life; symptom control; non-surgical management; disease progression; patient safety; clinical outcomes.

Akhmedov, O. (2020). Benign prostatic hyperplasia in men: Diagnosis and treatment. Medicine and Health, 12(3), 45–52.

Sobirov, R., & Qodirov, B. (2019). Conservative treatment methods and outcomes in benign prostatic hyperplasia. Andijan Medical Journal, 8(2), 33–40.

Tursunov, S. (2021). Urological diseases and their impact on patient quality of life. Tashkent: Medical Publishing.

Rahmonov, A. (2022). Benign prostatic hyperplasia: Pharmacological treatment and clinical outcomes. Uzbekistan Medical Journal, 15(1), 27–35.

Haile, E. S., Sotimehin, A. E., & Gill, B. C. (2024). Medical management of benign prostatic hyperplasia. Cleveland Clinic Journal of Medicine, 91(3), 163–170.

Al-Shukri, A. S. (2025). The relevance of using 5α-reductase inhibitors in the conservative management of benign prostatic hyperplasia: A review. Consilium Medicum, 27(08), 461–468.

Zhou, Y., Luo, Q., Wang, R., Zheng, D., Xiong, Y., & Zuo, J. (2025). Integrated management strategies for benign prostatic hyperplasia. Frontiers in Urology, 5, 1641171.

Govorov, A. V. (2017). Conservative management of benign prostatic hyperplasia: Are urologists satisfied? Urologiia, Suppl.3, 45–47.